Praxis ginagawang single-arm ang EMBRAVE3 elsunersen study

Ang EMBRAVE3 registrational study ng elsunersen sa SCN2A DEE ay agad na ginawang single-arm, baseline-controlled study na may 30 pasyente mula sa dating double-blind, sham-controlled trial. Lahat ng pasyente ay tatanggap ng elsunersen sa loob ng 24 linggo na sinusundan ng open-label extension. Ang Part A topline results ay inaasahan pa rin sa H1 2026.

Mahahalagang fact

Na-file: Dis 11, 2025, 09:23 PM
Kaganapan: Pagbabago sa trial registry
Direksyon: Positibo
Kumpanya: PRAXPraxis
Asset: relutrigine
Pinagmulan: SEC 8-K
Kumpiyansa: May source
Tagal: 24 linggo
Pagpapatala: 30 pasyente

Sipi mula sa source

prax-20251209 FALSE 0001689548 0001689548 2025-12-09 2025-12-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 PRAXIS PRECISION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39620 47-5195942 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Praxis Precision Medicines, Inc. 99 High Street , 30th Floor Boston , Massachusetts 02110 (Address of principal executive offices, including zip code) ( 617 ) 300-8460 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address,

SEC 8-K